HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Post-Pandemic Stocks

913.921

-19.967-2.14%

Number of Gainers:2

Number of Losers:15

Number of Flat:- -

PE:- -

High:930.611

Open:930.611

Low:904.457

Close:933.888

Volume:222.36M

Turnover:2.07B

Market Cap:614.44B

Float Cap:512.07B

Loading ...

Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest

Simply Wall St.

Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook

Ascletis Pharma Expects HY Loss of Rmb319.7 MLN

BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year

China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million

Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY

THOMSON REUTERS

Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others

THOMSON REUTERS

Junshi Biosciences Raises 700 Million Yuan Through Tech Innovation Bond Issuance

SBP Group's Novel Weight Management Therapy Gains Regulatory Nod for Clinical Trials

Henan Chemical Firm Commits 38 Million Yuan to Revamp Pharmaceutical Intermediate Facility

UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50

MT Newswires Live

Sino Biopharm Says NMPA Clears Tqf6422 Obesity Drug Candidate for Clinical Trial

Sino Biopharmaceutical - Application for Clinical Trial on Tqf6422 Injection "Actrii a/B Monoclonal Antibody" Approved by Nmpa

THOMSON REUTERS

Xinhua Pharmaceutical Gets Registration Certificate for Diabetes Mellitus Drug in China

MT Newswires Live

Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating

Shandong Xinhua Secures Regulatory Approval for Dapagliflozin Tablets

JD Health International Stock Rallies 1.6% in Hong Kong

CSPC Pharmaceutical Group Stock Falls 3.5% in Hong Kong, Underperforms Competitors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/BK1515/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"Post-Pandemic Stocks","latestPrice":913.9212,"timestamp":1788148339154,"preClose":933.88794,"halted":0,"volume":222359303,"delay":0,"changeRate":-0.02138,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-19.966736,"latestTime":"08-31 11:52:19","open":930.611,"high":930.611,"low":904.4565,"amount":2069043327,"amplitude":0.028006,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1788148800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788139800000,1788148800000],[1788152400000,1788163200000]],"pbRate":1.403188,"peRate":17.015388,"turnoverRate":0.003046,"increases":2,"decrements":15,"flats":0,"marketCap":614436890368,"floatMarketCap":512073730432},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":930.611,"amplitude":0.028006,"preClose":933.88794,"low":904.4565,"pbRate":"1.403188","latestPrice":913.9212,"volume":222359303,"delay":0,"open":930.611,"prevYearClose":1190.107,"prevWeekClose":933.888,"prevMonthClose":925.972,"prevQuarterClose":802.777,"fiveDayClose":929.009,"twentyDayClose":928.063,"sixtyDayClose":909.52,"secType":"PLATE","market":"HK","turnoverRate":0.003046,"peRate":17.015388,"marketCap":614436890368,"floatMarketCap":512073730432,"timestamp":1788148339154,"nameCN":"Post-Pandemic Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":2,"down":15,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661216000","title":"Sino Biopharmaceutical (SEHK:1177) Could Be 66% Below Fair Value As Earnings Lift Interest","url":"https://stock-news.laohu8.com/highlight/detail?id=2661216000","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661216000?lang=en_us&edition=fundamental","pubTime":"2026-08-22 16:18","pubTimestamp":1787386734,"startTime":"0","endTime":"0","summary":"Half year earnings update and why Sino Biopharmaceutical stock is in focus\nSino Biopharmaceutical (SEHK:1177) recently reported half year 2026 earnings, with sales of CNY 19,444.36 million and net income of CNY 3,434.6 million. Earnings per share from continuing operations also edged higher versus a year earlier.\nSee our latest analysis for Sino Biopharmaceutical.\nThe latest earnings release appears to have sharpened investor focus on Sino Biopharmaceutical, with the stock posting a 3.80% 1...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/sino-biopharmaceutical-sehk1177-could-be-66-below-fair-value","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1177/sino-biopharmaceutical-shares/news/sino-biopharmaceutical-sehk1177-could-be-66-below-fair-value","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VOTE","HK0000165453.HKD","01177","IE00BZ08YS42.EUR","FEBU","IE00BZ08YT58.USD","BK1191","JOYT","BK1521","BK1589","IE00BZ08YR35.GBP","GXDW","PMDE","RGLO","DCF","BK1515","VGFPF","DECU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661901362","title":"Niki BioSolutions Weighs Financing Options as Going-Concern Warning Clouds Post-Merger Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2661901362","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661901362?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:15","pubTimestamp":1787346928,"startTime":"0","endTime":"0","summary":"Niki BioSolutionsweighs financing options as going-concern warning clouds post-merger outlookOverviewUS biopharmaceutical developer's H1 net loss widened, with loss per share at $1.6Operating expenses","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0TG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","BK1515","BK1191","IE00BZ08YT58.USD","01177","BK1521","BK1161","BK1589","BK1587","BK4139","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1574","BK1583","02137","NIKI","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661291392","title":"Ascletis Pharma Expects HY Loss of Rmb319.7 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2661291392","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661291392?lang=en_us&edition=fundamental","pubTime":"2026-08-21 23:45","pubTimestamp":1787327122,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma Expects HY Loss Of RMB319.7 MLNAug 21 (Reuters)-Ascletis Pharma Inc1672.HK:EXPECTS LOSS OF RMB319.7 MILLION FOR H1 2026, UP 263.5% YOYEXPECTED HY RESULT AS RESEARCH AND DEVELOPMENT EXPENSES INCREASED 132.7% TO RMB341.7 MILLION, OTHERSFurther company coverage:1672.HK","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","BK1515","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149843220","title":"BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1149843220","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149843220?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:50","pubTimestamp":1787320219,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) has announced its interim results for 2026, with revenue reaching approximately RMB 42.091 billion, a modest increase of 0.61% year-on-year. Net profit attributable to...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600332","BK0096","BK0097","BK0239","00874","BK0012","BK0070","BK1606","BK0188","BK0196","BK1515","BK0175","BK1197","BK1521","BK1191","BK0183","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661932892","title":"China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2661932892","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661932892?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:25","pubTimestamp":1787318735,"startTime":"0","endTime":"0","summary":"China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distributionOverviewChina biomedical products maker's half-year revenue fell 9.8% yr/yr to RMB1.17 blnNet profit attrib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0140636845.USD","LU1960683339.HKD","LU1993786604.SGD","BK1191","06826","LU1226288253.USD","LU1152091754.HKD","BK1161","01093","IE00BZ08YR35.GBP","LU0072913022.USD","BK0239","LU0314109678.HKD","LU1226288170.HKD","LU0501845795.SGD","IE00B543WZ88.USD","LU0315179316.USD","LU0880133367.SGD","SG9999004220.SGD","LU1328277881.USD","688366","IE0008369823.USD","IE0008368742.USD","LU1807302812.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1813983027.USD","LU1152091168.USD","BK1521","LU1951186391.HKD","LU1226287792.SGD","KURE","LU2039709279.SGD","BK1593","BK1515","LU1226287875.USD","IE00B031HY20.USD","BK0251","LU0326950275.SGD","LU0067412154.USD","HK0000165453.HKD","IE00BZ08YT58.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188138907","title":"Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1188138907","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188138907?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:22","pubTimestamp":1787314947,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has issued a profit warning, forecasting a net loss attributable to equity shareholders of approximately RMB 319.7 million for the six months ending June 30, 2026. This...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1515","01477","01672","BK1191","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661115260","title":"Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661115260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661115260?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:01","pubTimestamp":1787313666,"startTime":"0","endTime":"0","summary":"Ascletis Pharma sees H1 loss widening to RMB 319.7 millionAscletis flagged a wider loss attributable to equity shareholders of about RMB 319.7 million for the six months ended June 30, 2026.Compares w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL949XQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260941","title":"Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260941?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313633,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260157","title":"Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260157?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313633,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1515","BK1161","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120137209","title":"Junshi Biosciences Raises 700 Million Yuan Through Tech Innovation Bond Issuance","url":"https://stock-news.laohu8.com/highlight/detail?id=1120137209","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120137209?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:50","pubTimestamp":1787313012,"startTime":"0","endTime":"0","summary":"Junshi Biosciences (01877) has announced the successful completion of its third technology innovation bond issuance for the 2026 fiscal year, with the raised funds credited to the company's account...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1583","BK1515","01877","BNDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163803683","title":"SBP Group's Novel Weight Management Therapy Gains Regulatory Nod for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1163803683","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163803683?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:38","pubTimestamp":1787308697,"startTime":"0","endTime":"0","summary":"SBP GROUP (01177) has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., has received approval from the Center for Drug Evaluation (CDE) of China's National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","01177","IBBJ","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1515","HK0000165453.HKD","IBBQ","BK1589","PSYK","BK1191","IE00BZ08YS42.EUR","MDTX","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143378344","title":"Henan Chemical Firm Commits 38 Million Yuan to Revamp Pharmaceutical Intermediate Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=1143378344","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143378344?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:31","pubTimestamp":1787308286,"startTime":"0","endTime":"0","summary":"A renovation project for a pharmaceutical intermediate production line in Henan Province has entered its second public review phase, with the developer planning a total investment of 38 million...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","BK1574","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661646202","title":"UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2661646202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661646202?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:26","pubTimestamp":1787307972,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) has an average rating of overweight and mean price target of HK$12.07, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1226287792.SGD","LU1226288253.USD","LU0072913022.USD","LU1807302812.USD","LU1152091168.USD","LU1226288170.HKD","LU0140636845.USD","LU1960683339.HKD","LU1226287529.USD","LU1152091754.HKD","LU0067412154.USD","BK1521","LU1813983027.USD","LU0315179316.USD","LU1993786604.SGD","SG9999004220.SGD","IE0008368742.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","LU0880133367.SGD","LU1008478684.HKD","HK0000165453.HKD","LU1226287875.USD","BK1515","KURE","IE00BZ08YT58.USD","IE0008369823.USD","LU0326950275.SGD","01093","IE00B031HY20.USD","IE00B543WZ88.USD","LU0314109678.HKD","LU0501845795.SGD","LU1328277881.USD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU2039709279.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264881","title":"Sino Biopharm Says NMPA Clears Tqf6422 Obesity Drug Candidate for Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264881","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661264881?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:17","pubTimestamp":1787307470,"startTime":"0","endTime":"0","summary":"Sino Biopharm says NMPA clears TQF6422 obesity drug candidate for clinical trialSino Biopharmaceutical unit Chia Tai Tianqing secured NMPA clearance to start clinical studies of TQF6422 obesity inject","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL71ZXMW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","HK0000165453.HKD","01177","BK1515","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1191","BK1589","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661226102","title":"Sino Biopharmaceutical - Application for Clinical Trial on Tqf6422 Injection \"Actrii a/B Monoclonal Antibody\" Approved by Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661226102?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:17","pubTimestamp":1787307451,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1QX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01177","BK1589","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","BK1521","HK0000165453.HKD","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661613712","title":"Xinhua Pharmaceutical Gets Registration Certificate for Diabetes Mellitus Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2661613712","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661613712?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:56","pubTimestamp":1787306209,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical  obtained the drug registration certificate for its Dapagliflozin Tablets approved by China's National Medical Products Administration.The product is used in adult patients with type 2 diabetes mellitus, according to a Friday Hong Kong bourse filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK0164","BK0239","00719","BK1515","000756"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191293609","title":"Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1191293609","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191293609?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:20","pubTimestamp":1787304047,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research report reaffirming its \"Buy\" rating on CSPC Pharma (01093), while lifting the target price from HK$12.14 to HK$12.56. The firm has also raised its earnings...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B031HY20.USD","BK1521","KURE","HK0000165453.HKD","SG9999004220.SGD","LU0314109678.HKD","LU0072913022.USD","LU0140636845.USD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU1226288253.USD","LU0880133367.SGD","LU1951186391.HKD","LU1993786604.SGD","IE00B5MMRT66.SGD","LU1960683339.HKD","LU1328277881.USD","LU1226287875.USD","LU0067412154.USD","BK1515","LU0501845795.SGD","IE00BZ08YR35.GBP","IE0008369823.USD","LU0315179316.USD","LU1226288170.HKD","LU1008478684.HKD","BK1191","LU1152091754.HKD","EWH","IE00BZ08YT58.USD","LU0326950275.SGD","LU1226287529.USD","LU1807302812.USD","LU1152091168.USD","LU1813983027.USD","LU1226287792.SGD","01093","LU2039709279.SGD","IE0008368742.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129621267","title":"Shandong Xinhua Secures Regulatory Approval for Dapagliflozin Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1129621267","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129621267?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:50","pubTimestamp":1787302225,"startTime":"0","endTime":"0","summary":"Shandong Xinhua Pharmaceutical Co, listed under 00719.HK, has announced the receipt of the Drug Registration Certificate for dapagliflozin tablets, officially approved by China's National Medical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00719","BK1191","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661263074","title":"JD Health International Stock Rallies 1.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2661263074","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661263074?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:33","pubTimestamp":1787301180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of JD Health International Inc. rose 1.6% to 38.66 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 26009.46.JD Health International Inc. closed 46% short of its 52-week high of HK$71.70, which the company achieved Jan. 15.Trading volume totaled 9.1 million shares, compared to the 50-day average of 10.5 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","LU0051755006.USD","BK1591","SGXZ62798434.SGD","06618","LU0456827905.SGD","BK1515","BK1571","86618","BK1615","BK1247","BK1142","BK1589","SGXZ86797644.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661026306","title":"CSPC Pharmaceutical Group Stock Falls 3.5% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661026306","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661026306?lang=en_us&edition=fundamental","pubTime":"2026-08-21 16:31","pubTimestamp":1787301060,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. slid 3.5% to 9.19 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 26009.46.CSPC Pharmaceutical Group Ltd. closed 21% below its 52-week high of HK$11.63, which the company reached Sept. 9.The stock underperformed when compared to some of its competitors, as Sino Biopharmaceutical Ltd. rose 3.8%, SSY Group Ltd. rose 1.2%, and United Laboratories International Holdings Ltd. rose 3.4%.Trading volume totaled 135.4 million shares, compared to the 50-day average of 98.2 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951186391.HKD","HK0000165453.HKD","BK1191","LU0314109678.HKD","LU0067412154.USD","01093","IE00BZ08YS42.EUR","IE0008369823.USD","LU1226288170.HKD","LU1328277881.USD","LU1226287529.USD","LU1807302812.USD","LU1226287875.USD","LU1960683339.HKD","LU1008478684.HKD","BK1521","IE00BZ08YT58.USD","LU1226287792.SGD","LU1226288253.USD","LU0140636845.USD","LU2039709279.SGD","LU0072913022.USD","LU0315179316.USD","LU1813983027.USD","LU1993786604.SGD","LU0326950275.SGD","KURE","IE00B5MMRT66.SGD","LU0501845795.SGD","SG9999004220.SGD","IE00B543WZ88.USD","LU0880133367.SGD","IE0008368742.USD","IE00B031HY20.USD","LU1152091754.HKD","BK1515","IE00BZ08YR35.GBP","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":8,"totalSize":267,"code":"91000000","status":"200"}]}}